This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Alvotech has moved one step closer to entering the Eylea (aflibercept 2 mg) biosimilar market, after a European Medicines Agency (EMA) panel recommended approval of its copycat biologic. Go deeper with GlobalData Reports LOA and PTSR Model - Aflibercept Biosimilar in Age Related Macular. CucuMberStudio via Shutterstock.
Reports Prescriber Opinions on Biosimilars in Immunology Data Insights The gold standard of business intelligence. We may still continue to send you service-related and other non-promotional communications. Reports Prescriber Opinions on Biosimilars in Immunology Data Insights The gold standard of business intelligence.
Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Find out more Sign up for our daily news round-up!
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Kaftrio loses patient protection in 2037, at which point biosimilars are set to enter the market. Trikafta, known under the brand name Kaftrio in Europe, is the best-selling cystic fibrosis drug in the world, generating revenue of $11.02bn in 2024. Historically, this erodes the market dominance held by the branded drug.
Biosimilars and generics flood the market upon patent loss, which exerts pricing pressure on the branded product. There has been a push by the Trump administration to increase biosimilar and generic drug use in the US. Biosimilars and generics can be as much as 80% cheaper than branded alternatives.
We may still continue to send you service-related and other non-promotional communications. By Cytiva Thematic You have a right to withdraw your consent at any time, by clicking here. For more information relating to our privacy practices, we invite you to review our privacy policy. Sign up for our daily news round-up!
Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Sign up for our daily news round-up!
They had their own lawyers and communications staff and legislative affairs people; they managed their own hearings to Congress and appropriations requests. There was essentially a fiefdom culture with many different centres at the agency. Sometimes they didnt talk. Each centre was autonomous. They had 12 travel offices.
Zentiva Group has entered into a licence and supply agreement with pharmaceutical company Lupin for the commercialisation of the latter’s biosimilar Certolizumab Pegol, a tumour necrosis factor alpha (TNFα) inhibitor medicine, across several markets. The partnership will enhance the availability of the affordable biosimilar on a global scale.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Can pharma tariffs “Make America Manufacture Again”?
Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU). Clinical trials have demonstrated that both biosimilars match the reference product’s safety, quality and efficacy standards.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Can pharma tariffs “Make America Manufacture Again”?
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Can pharma tariffs “Make America Manufacture Again”?
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Go deeper with GlobalData Reports LOA and PTSR Model - Bevacizumab Biosimilar in Endometrial Cancer Reports LOA and PTSR Model - Iparomlimab + Tuvonralimab in Nasopharyngeal C. NPC is a rare type of cancer in which malignant cells are formed in the upper part of the throat behind the nose. Find out more Sign up for our daily news round-up!
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
In February 2025, Teva and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). Can pharma tariffs “Make America Manufacture Again”? This targeted method could significantly improve patient outcomes across multiple oncology diseases.
About the author Natalie Schibell is vice president of market strategy and communications at Aetion, where she oversees enterprise market intelligence, competitive insights, and strategic positioning across healthcare and life sciences sectors. Oncology On the forefront of healthcare change, turning innovative sc.
Trump’s ‘most favoured nation’ model comes at a time when the administration has been vocal on its support for generics and biosimilars – copycat drugs that offer patients a cheaper entry point to treatment. It also goes some way to explaining the sheer volume of patients turning to compounded GLP-1RAs for weight loss.
R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems. R&D Deep Dive: Research and Development 2025 Every breakthrough in medicine, every new treatment that changes lives, starts with research.
While the overall MG market is expected to experience growth until 2034, continued generic erosion and the entry of biosimilars will be important barriers to growth. Generic erosion and the entry of biosimilars are expected to be particularly significant in the US MG market. Can pharma tariffs “Make America Manufacture Again”?
Explainability is also crucial, particularly for areas of drug development, where AI outputs must be effectively communicated to meet regulatory requirements and build trust among clinicians, regulators, and patients.
Go deeper with GlobalData Reports Biosimilars in Pharmaceuticals: Peptide-based compositions for Alzh. Can pharma tariffs “Make America Manufacture Again”? Over the past few decades, Alzheimer’s research and development (R&D) has seen a low success rate due to failure to demonstrate efficacy in clinical trials.
R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems. R&D Deep Dive: Research and Development 2025 Every breakthrough in medicine, every new treatment that changes lives, starts with research.
Partner Content Streamline Supply Chain Communications to Optimize Phase Appropriate QC Testing, Comparability & GMP Manufacturing of Raw Materials & Achieve Regulatory Compliance of Scalable Cell & Gene Therapies. Oncology Liver cancer diagnostic gets FDA breakthrough status, with P.
This Revised Draft Guidance provides considerations for manufacturers, packers or distributors (dubbed “firms”) of prescription biological reference products, biosimilar products, and interchangeable biosimilar products presenting data and information about such products in promotional materials in a truthful and non-misleading way.
In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. They employed hundreds of new salespeople to detail doctors and hospitals, spent millions on TV and magazine ads and handed out masses of free samples. Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content